Mumbai, Oct. 21 -- The product was manufactured at Innoxel's finished dosage facility in Vadodara, Gujarat, and launched by its sponsor partner. The company did not disclose the product name or sponsor's identity due to confidentiality obligations.

The launch marks Innoxel's transition from earning licensing income to generating recurring revenue from commercial supplies. The company expects to commercialise a second CMO product in FY27, with additional launches planned over the next two quarters and into FY28.

Innoxel reported revenue of Rs 72.4 crore in FY26, entirely from licensing. This included Rs 17.1 crore in upfront payments and Rs 55.3 crore linked to milestones.

The Vadodara facility received an Establishment Inspection Repor...